AlphaFold predicted structure
PDE3A · Q14432

Mean pLDDT
60.3/ 100
Low
1,141 residues
Confidence breakdown
- Very high(≥ 90)28%
- Confident(70–90)12%
- Low(50–70)9%
- Very low(< 50)51%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
phosphodiesterase 3A
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
Fetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedLimb disorders
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownSkeletal dysplasia
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedBrachydactyly - arterial hypertension
brachydactyly-arterial hypertension syndrome
coronary artery disorder
cardiovascular disorder
stroke disorder
asthma
heart failure
essential thrombocythemia
Airway obstruction
chronic obstructive pulmonary disease
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes (PubMed:1315035, PubMed:25961942, PubMed:8155697, PubMed:8695850). Also has activity toward cUMP (PubMed:27975297). Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling (PubMed:31420216, PubMed:34707099)
Curated MONDO disease pages that list PDE3A among their top associated genes.
PDE3A · Q14432

Mean pLDDT
60.3/ 100
Low
1,141 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0